Proteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities
Article first published online: 9 JUN 2014
© 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Cellular and Molecular Medicine
Volume 18, Issue 7, pages 1239–1246, July 2014
How to Cite
López Villar, E., Wu, D., Cho, W. C., Madero, L. and Wang, X. (2014), Proteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities. Journal of Cellular and Molecular Medicine, 18: 1239–1246. doi: 10.1111/jcmm.12319
- Issue published online: 30 JUL 2014
- Article first published online: 9 JUN 2014
- Manuscript Accepted: 4 APR 2014
- Manuscript Received: 17 JAN 2014
- ISCIII SNS Funding . Grant Number: PI13/02475 FIS
- Shanghai Leading Academic Discipline Project. Grant Number: B115
- Shanghai Young Clinicians Nurturing Plan
- Zhongshan Distinguished Professor Grant
- National Nature Science Foundation of China. Grant Numbers: 91230204, 81270099, 81320108001
- Shanghai Committee of Science and Technology. Grant Numbers: 12JC1402200, 12431900207, 11410708600
- acute lymphoblastic leukaemia;
There are important breakthroughs in the treatment of paediatric acute lymphoblastic leukaemia (ALL) since 1950, by which the prognosis of the child majority suffered from ALL has been improved. However, there are urgent needs to have disease-specific biomarkers to monitor the therapeutic efficacy and predict the patient prognosis. The present study overviewed proteomics-based research on paediatric ALL to discuss important advances to combat cancer cells and search novel and real protein biomarkers of resistance or sensitivity to drugs which target the signalling networks. We highlighted the importance and significance of a proper phospho-quantitative design and strategy for paediatric ALL between relapse and remission, when human body fluids from cerebrospinal, peripheral blood, or bone-marrow were applied. The present article also assessed the schedule for the analysis of body fluids from patients at different states, importance of proteomics-based tools to discover ALL-specific and sensitive biomarkers, to stimulate paediatric ALL research via proteomics to ‘build’ the reference map of the signalling networks from leukemic cells at relapse, and to monitor significant clinical therapies for ALL-relapse.